Related Experiment Video
Updated: Jun 23, 2026
The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
Published on: March 13, 2014
A retrospective analysis of coagulation function indicators in acute fatty liver of pregnancy
Panpan Zhai1, Jing Hu2, Xueting Ou1
1Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Background:
Acute Fatty Liver of Pregnancy (AFLP) is a rare but life-threatening obstetric emergency. Coagulation dysfunction is a core pathophysiological feature and a key risk factor for adverse events. This study retrospectively analyzed 92 AFLP patients to evaluate the association between coagulation indicators and multiple adverse outcomes, and obtain primary indicator that can predict the severity of disease.
Methods:
This retrospective cohort study included 92 AFLP patients treated at our hospital from 2017 to 2023. We collected clinical manifestations, laboratory data, and composite adverse outcomes including ICU admission, maternal complications. Logistic regression with variance inflation factor (VIF) diagnostics was used to analyze independent correlates of adverse outcomes. Receiver operating characteristic (ROC) analysis was performed for single indicators.
Results:
INR (AUC 0.837) and PT (AUC 0.837) showed the strongest individual predictive performance for composite adverse outcomes, these two indicators are the mostsensitive in predicting severity of AFLP. The VIF value of PT is greater than 10, indicating severe multicollinearity. The VIF value of INR was less than 5, and was independently associated with higher rates of MODS, DIC, postpartum hemorrhage.
Conclusion:
Coagulation function indicators are strongly associated with adverse clinical events in AFLP. INR provides improved risk stratification performance over other markers and may support clinical decision-making. This preliminary indicator requires external validation before routine clinical use.
